1. Scrip
  2. >>Therapy Areas

High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share

As Roche’s Vabysmo Mounts Threat

 
• By Ayisha Sharma

The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.    

View inside human eye disorders - showing retina, optic nerve and macula.
Eylea Biosimilars Could Reach The Market In 2024 • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. and Bayer AG’s Eylea has shown improved durability at a higher dose in two pivotal ocular disease studies, helping retain its competitiveness against the likes of Roche Holding AG’s Vabysmo.

The Phase III PHOTON and PULSAR studies investigated aflibercept, the active ingredient in Eylea, at a high 8mg dose in two different regimens – once every 16 weeks and once every 12 weeks

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.